Document is current
Any future updates will be listed below
-
Authors
Grabinger, Thomas
Haerry, David
Jackson-Perry, David
Gattiker, Marlon
Oberle, Corinna
Braun, Dominique L.
Darling, Katharine E. A.
-
Funding
Funding for this research was provided by:
Gilead Sciences Sàrl, Switzerland
- License Information
-
More Information
Article History
Received: 10 October 2025
Accepted: 28 April 2026
First Online: 18 May 2026
Declarations
:
: We confirm that this project was conducted in accordance with relevant national and international guidelines and regulations, including the principles of the Declaration of Helsinki. As the survey was designed as a quality assurance project, no formal ethics approval or waiver was required, based on a national Swissethics-issued decree (Version 1.0, 01.02.2020) [ ]. The survey design was not in any form empirical/experimental and no intervention, no vulnerable population groups and no treatments were involved. Study participation was voluntary and informed consent was obtained electronically from all participants prior to participation. Participants were informed about the purpose of the project, data anonymity, and their right to withdraw at any time. We certify that the survey was conducted in accordance with the principles of general data protection regulation (GDPR) and the code of conduct of the European society for opinion and marketing research (ESOMAR) international code on market, opinion and social research and data analytics ( ).All survey participants declared their consent to participate.
: Not applicable.
: TG and CO are employees and stockholders of Gilead Sciences. DH has received fees related to consultancies with AstraZeneca, Gilead, UCB, ViiV Healthcare, a travel grant from Gilead, and institutional funding from AstraZeneca, Gilead, GSK, A. Menarini Pharma, MSD, Pfizer and ViiV Healthcare. DJP's institution has received project grants, sponsorship to attend specialist meetings, and honoraria for presentations from Gilead Sciences and ViiV, and project grants from MSD. DLB has received fees unrelated to this work for lectures and advisory boards from Gilead, MSD and ViiV. KEAD has received fees unrelated to this work for lectures and expert opinion panels from Gilead and for advisory board participation from MSD. The other authors declare no conflicts of interest.
